Palatin Technologies, Inc. (NYSE American: PTN) announced that enrollment in the PL9643 MELODY-1 Phase 3 study in dry eye ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE